Skip to content
ClinCalc Pro
Menu
5-HT3 Receptor Antagonist (Antiemetic — Hyperemesis Gravidarum)

Ondansetron (Hyperemesis Gravidarum)

Brand names: Zofran

Ondansetron is a 5-HT3 receptor antagonist antiemetic used in pregnancy for nausea and vomiting, including hyperemesis gravidarum, when first-line antiemetics are inadequate.

Dosing — not shown for this use

The product information we hold does not support a dose for this page's specific use, route or population, so none is shown. Follow your local or national guideline, and confirm against the product SmPC.

The licensed dosing — for the medicine's licensed uses, which may differ from this page's — is on Ondansetron.

Clinical monograph

How it works

It blocks serotonin 5-HT3 receptors centrally and on vagal afferents in the gastrointestinal tract, interrupting the emetic reflex.

Prescribing in practice

  • Use in the first trimester only after first-line antiemetics have failed, after a discussion of a small possible increase in the risk of orofacial clefts noted in some studies, in line with MHRA advice.
  • It prolongs the QT interval, so caution is needed with electrolyte disturbance (common in hyperemesis) and other QT-prolonging drugs.
  • Constipation is a common adverse effect.

Monitoring

Correct dehydration and electrolyte disturbances and consider ECG monitoring of the QT interval where risk factors are present.

Counselling the patient

  • This is used when other anti-sickness medicines have not worked, after weighing the benefits and risks in early pregnancy.
  • Constipation is common; maintain fluids and fibre as able.
  • Report palpitations or fainting.

Evidence & guidelines

MHRA advises caution with ondansetron in the first trimester owing to a possible small increased risk of orofacial clefts; RCOG guidance positions it as a later-line antiemetic in pregnancy.

Reference: RCOG Green-top 69 Hyperemesis Gravidarum (2024); MHRA Drug Safety Update (ondansetron pregnancy); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.